For the year ending 2025-12-31.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| Research and development | 44,845 | |||
| General and administrative | 18,707 | |||
| Total operating expenses | 63,552 | |||
| Loss from operations | -63,552 | |||
| Interest income | 5,357 | |||
| Other income (expense), net | -2 | |||
| Total other income, net | 5,355 | |||
| Net loss | -58,197 | |||
| Unrealized gain (loss) on short-term investments | -57 | |||
| Comprehensive loss | -58,254 | |||
| Basic EPS | -2.6 | |||
| Diluted EPS | -2.6 | |||
| Basic Average Shares | 22,360,000 | |||
| Diluted Average Shares | 22,360,000 | |||
Boundless Bio, Inc. (BOLD)
Boundless Bio, Inc. (BOLD)